Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide in Type 2 Diabetes
NCT07754461Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 5
01
Overview
A Phase 3 trial of survodutide in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07754461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754461.